Skip to main content
Erschienen in: Supportive Care in Cancer 9/2007

01.09.2007 | Short Communication

Determining mucosal barrier injury to the oesophagus using CT scan

verfasst von: N. M. A. Blijlevens, J. P. Donnelly, D. Yakar, C. E. van Die, T. de Witte

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Oral mucositis is recognised as one of the most debilitating complications of high-dose cytostatic chemotherapy used to prepare for haematopoietic stem cell transplantation (HSCT), but very little is known about oesophageal mucositis, as endoscopy is not routinely performed.

Materials and methods

We incorporate the computed tomography (CT) scan in the diagnostic workup of fever during neutropenia to detect evidence of pulmonary complications. This allowed us to evaluate whether mucosal barrier injury to the oesophagus can be determined. We selected 46 patients without oesophageal cancer or immune suppression (controls), who had a normal oesophagus, and measured the mucosal thickness at the upper part (UP), middle part (MP) and lower part (LP) of the oesophagus. Next, we selected 30 patients having a CT scan done for diagnostic purposes within 14 days after HSCT and measured mucosal thickness at the same levels. We also scored oral mucositis and gut toxicity.

Results

The mucosal thickness of the UP, MP and LP, respectively, for the controls (mean ± SD) was 4.1 mm (±1.1), 4.2 mm (±1.2) and 4.8 mm (±1.3), and the corresponding values for the subjects were 5.9 mm (±2.2), 5.9 mm (±2.0) and 7.7 mm (±3.0). Analysis of variance showed statistically significant differences between subjects and controls at all oesophageal levels. All patients suffered from severe oral mucositis at the time.

Conclusion

Hence, mucosal barrier injury to the oesophagus can be objectively measured using CT scan.
Literatur
1.
Zurück zum Zitat Blijlevens NMA, Donnelly JP, De Pauw BE (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:1269–1278PubMedCrossRef Blijlevens NMA, Donnelly JP, De Pauw BE (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:1269–1278PubMedCrossRef
2.
Zurück zum Zitat Blijlevens NMA, Donnelly JP, de Pauw BE (2002) Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117(2):259–264 (May)PubMedCrossRef Blijlevens NMA, Donnelly JP, de Pauw BE (2002) Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117(2):259–264 (May)PubMedCrossRef
3.
Zurück zum Zitat Blijlevens NMA, Donnelly JP, DePauw BE (2005) Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 36(8):703–707 (October)PubMedCrossRef Blijlevens NMA, Donnelly JP, DePauw BE (2005) Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 36(8):703–707 (October)PubMedCrossRef
4.
Zurück zum Zitat Blijlevens NMA, van’t Land B, Donnelly JP, M’Rabet L, DePauw BE (2004) Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 12:227–233PubMedCrossRef Blijlevens NMA, van’t Land B, Donnelly JP, M’Rabet L, DePauw BE (2004) Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 12:227–233PubMedCrossRef
5.
Zurück zum Zitat Cartoni C, Dragoni F, Micozzi A, Pescarmona E, Mecarocci S, Chirletti P, Concetta Petti M, Meloni G, Mandelli F (2001) Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol 19:756–761PubMed Cartoni C, Dragoni F, Micozzi A, Pescarmona E, Mecarocci S, Chirletti P, Concetta Petti M, Meloni G, Mandelli F (2001) Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol 19:756–761PubMed
6.
Zurück zum Zitat Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539PubMedCrossRef Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539PubMedCrossRef
7.
Zurück zum Zitat Lal DR, Foroutan HR, Su WT, Wolden SL, Boulad F, La Quaglia MP (2006) The management of treatment-related esophageal complications in children and adolescents with cancer. J Pediatr Surg 41(3):495–499 (March)PubMedCrossRef Lal DR, Foroutan HR, Su WT, Wolden SL, Boulad F, La Quaglia MP (2006) The management of treatment-related esophageal complications in children and adolescents with cancer. J Pediatr Surg 41(3):495–499 (March)PubMedCrossRef
8.
Zurück zum Zitat MASCC/ISOO, T.M.s.g.o. (2005) Summary of evidence-based clinical practice guidelines for care of patients with oral and gastrointestinal mucositis (2005 updat). http://www.mascc.org/ Ref Type: Internet Communication MASCC/ISOO, T.M.s.g.o. (2005) Summary of evidence-based clinical practice guidelines for care of patients with oral and gastrointestinal mucositis (2005 updat). http://​www.​mascc.​org/​ Ref Type: Internet Communication
10.
Zurück zum Zitat Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Karlsson U, Dutta S, Midyett A, Barloon J, Sallah S (2005) Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 61(3):772–778 (March 1)PubMedCrossRef Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Karlsson U, Dutta S, Midyett A, Barloon J, Sallah S (2005) Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 61(3):772–778 (March 1)PubMedCrossRef
11.
Zurück zum Zitat Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R (2006) Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66(1):100–107PubMedCrossRef Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R (2006) Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66(1):100–107PubMedCrossRef
12.
Zurück zum Zitat Yang VX, Tang SJ, Gordon ML, Qi B, Gardiner G, Cirocco M, Kortan P, Haber GB, Kandel G, Vitkin IA, Wilson BC, Marcon NE (2005) Endoscopic Doppler optical coherence tomography in the human GI tract: initial experience. Gastrointest Endosc 61(7):879–890 (June)PubMedCrossRef Yang VX, Tang SJ, Gordon ML, Qi B, Gardiner G, Cirocco M, Kortan P, Haber GB, Kandel G, Vitkin IA, Wilson BC, Marcon NE (2005) Endoscopic Doppler optical coherence tomography in the human GI tract: initial experience. Gastrointest Endosc 61(7):879–890 (June)PubMedCrossRef
Metadaten
Titel
Determining mucosal barrier injury to the oesophagus using CT scan
verfasst von
N. M. A. Blijlevens
J. P. Donnelly
D. Yakar
C. E. van Die
T. de Witte
Publikationsdatum
01.09.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0192-9

Weitere Artikel der Ausgabe 9/2007

Supportive Care in Cancer 9/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.